Amivantamab and Mobocertinib for EGFR Exon-20 Disease - Lung Cancer Video Library

ASCO 2021 Lung Recap: Amivantamab and Mobocertinib for EGFR Exon 20Подробнее

Amivantamab 和 Mobocertinib：用于对抗 EGFR 外显子 20 插入突变 East Asian Lung Cancer Video LibraryПодробнее

Emerging Treatments and Clinical Trials for EGFR Exon-20 - Lung Cancer Video LibraryПодробнее

Treating Non–Small Cell Lung Cancer With an EGFR Exon 20 InsertionПодробнее

Amivantamab and lazertinib in treatment-naïve EGFR-mutant NSCLCПодробнее

Current treatments and challenges for patients with EGFR exon 20 insertion-positive NSCLCПодробнее

EGFR Exon-20 Mutation - Lung Cancer Video LibraryПодробнее

Amivantamab and Mobocertinib: Side Effects and Treatment Timing - Lung CancerПодробнее

Testing Methods to Discover EGFR Exon-20 Disease - Lung Cancer Video LibraryПодробнее

Amivantamab and Lazertinib in EGFR MET+ Disease - 2022 Program: Targeted Therapies Forum - EnglishПодробнее

Amivantamab in patients with EGFR Ex20ins-mutated NSCLCПодробнее

Treatments for patients with NSCLC carrying EGFR exon 20 insertionsПодробнее

Q&A: What is the Efficacy of Amivantamab and Lazertinib? - Targeted Therapies in Lung Cancer 2023Подробнее

Amivantamab Lazertinib Combo for Non-Small Cell Lung Cancer: Novel Mechanisms of ActionПодробнее

Managing patients with EGFR exon 20 ins in NSCLC and EGFR TKI toxicityПодробнее

Finding Clinical Trials for RET+ Disease - Lung Cancer Video LibraryПодробнее

The evolving treatment landscape for NSCLC with EGFR exon 20 insertion mutationsПодробнее

PROs in PAPILLON trial: amivantamab + chemo for EGFR Exon 20 NSCLCПодробнее

CHRYSALIS: Amivantamab for EGFR exon 20 insertion mutant NSCLCПодробнее